Follicular Lymphoma

Treatment with the CD19-targeted chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (liso-cel, formally known as JCAR017) demonstrated a complete response rate of 63% and an objective response rate of 81% in patients with relapsed/refractory diffuse large B-cell lymphoma.

Combining consolidative radioimmunotherapy and sequential maintenance rituximab following chemoimmunotherapy improved progression-free survival at 3 years in patients with previously untreated follicular lymphoma, according to findings from the phase II SWOG S0801 study recently published in <em>The Lancet Hematology</em>.

Based on supporting data from the phase III DUO trial and the phase II DYNAMO study, duvelisib has been submitted to the FDA for a full approval&nbsp;for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma.

Lymphoma expert Andrew M. Evens, DO, MSc, FACP, has joined Rutgers Cancer Institute of New Jersey as associate director. He is also serving as medical director of the oncology service line at RWJBarnabas Health. Evens will focus on integrated cancer care delivery in his roles across both institutions.

Progression-free survival was improved by nearly 15% with CHOP-RIT compared with R-CHOP alone in previously untreated patients with follicular lymphoma,&nbsp;according to findings from the phase III SWOG-S0016 trial published in the <em>Journal of Clinical Oncology</em>.

Pfizer has announced that PF-05280586, a biosimilar for rituximab, has delivered positive top-line results, meeting its primary endpoint for overall response rate in the&nbsp;in the phase III REFLECTIONS B3281006 trial for patients with follicular lymphoma.

Peter Martin, MD, discusses a phase I, open-label, multicenter trial of oral azacitidine (Vidaza) plus R-CHOP in people with high-risk, previously untreated DLBCL, grade 3B follicular lymphoma, or transformed lymphoma.

Jane N. Winter, MD,&nbsp;discusses recent updates in the field of follicular lymphoma, the importance of finding ways to identify patient populations, and challenges that still lie ahead.

Peter Martin, MD,&nbsp;assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a phase I, open-label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or transformed lymphoma.

Narendranath Epperla, MD,&nbsp;discusses the phase III GALLIUM trial, and the evolving treatment landscape for patients with follicular lymphoma and mantle cell lymphoma.

Jane N. Winter, MD,&nbsp;professor of medicine, Division of Hematology/Oncology, Feinberg School of Medicine at Northwestern University, discusses the importance of identifying and treating patients with follicular lymphoma (FL) who experience progression of their disease.&nbsp;

Long-term follow-up results of the FOLL05 trial confirm the efficacy of immunochemotherapy regimens for patients with previously untreated advanced-stage follicular lymphoma, according to findings of a post-hoc analysis recently published in the <em>Journal of Clinical Oncology </em>covering a median 7 years of follow-up.

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the interim analysis of a study exploring the safety and efficacy of atezolizumab (Tecentriq) in combination with obinutuzumab (Gazya) and bendamustine in patients with previously untreated follicular lymphoma.

Treatment with the novel PD-1 inhibitor cemiplimab induced responses in half of the patients with&nbsp;Hodgkin lymphoma in a phase I study of patients with B-lymphoid malignancies; among patients with&nbsp;B-cell non-Hodgkin lymphoma treated with the monotherapy, the overall response rate was 11.1%, according to a poster presentation at the 2017 ASH Annual Meeting.&nbsp;

Treatment with&nbsp;tisagenlecleucel (Kymriah) continues to excite the possibilities seen with chimeric antigen receptor T-cell therapy with impressive responses seen with the therapy in patients with&nbsp;relapsed/refractory diffuse large B-cell lymphoma. In the phase II JULIET trial, an overall response rate of 53.1%&nbsp;was observed, according to findings presented at the ASH Annual Meeting.&nbsp;

Pembrolizumab (Keytruda) has received a priority review from the FDA for a supplemental biologics license application (sBLA) for the treatment of&nbsp;adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL), according to a press release from Merck,&nbsp;the manufacturer of pembrolizumab. The findings were first presented at the 14th International Conference on Malignant Lymphoma and updated data were recently presented at the 2017 ASH Annual Meeting.

According to results of a phase Ib/II trial presented at the 2017 ASH Annual Meeting, the frontline triplet regimen of atezolizumab (Tecentriq), obinutuzumab (Gazyva), and bendamustine was associated with an overall response rate (ORR) of 85% (Modified Lugano criteria; independent review) in patients with follicular lymphoma.

The addition of brentuximab vedotin (Adcetris) to doxorubicin, vinblastine, and dacarbazine (A+AVD) reduced the risk of progression and death by 23% in patients with advanced-stage Hodgkin lymphoma (HL) compared with standard&nbsp;ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) chemotherapy, according to results of the phase III ECHELON-1 clinical trial.&nbsp;

Mogamulizumab improved progression-free survival in previously treated patients with cutaneous T-cell lymphoma by 4.6 months compared with vorinostat (Zolinza),&nbsp;according to findings from the phase III MAVORIC study.

A biologics license application for mogamulizumab has been granted a priority review by the FDA for the&nbsp;treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy,&nbsp;Kyowa Hakko Kirin, the manufacturer of the anti-CCR4 monoclonal antibody, has announced.

Obinutuzumab (Gazyva) has been approved by the FDA in combination with chemotherapy, followed by&nbsp;obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma,&nbsp;according to Genentech, the manufacturer of the therapy.

Based primarily on findings from the phase II CHRONOS-1 trial, copanlisib (Aliqopa) has received an accelerated approval from the FDA as a treatment for patients with relapsed follicular lymphoma who have received at least 2 prior systemic therapies.

A biologics license application for the rituximab biosimilar Rixathon has been accepted by the FDA, according to Sandoz, the company developing the treatment.&nbsp;If it receives approval, rixathon would be indicated for&nbsp;follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia, as well as for rheumatoid arthritis.

A supplemental biologics license application for obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, has been granted a priority review by the FDA for the first-line treatment of patients with follicular lymphoma.

Obinutuzumab (Gazyvaro, EU; Gazyva, US) has been recommended for approval by the European Medicines Agency&rsquo;s&nbsp;Committee for Medicinal Products for Human Use (CHMP) in the frontline setting for the treatment of patients with follicular lymphoma.